Vivalyx, a Aachen, Germany-based organ vitality tech company, raised €5.4M in Seed funding.
The round was led by BVP and TechVision Fonds.
The company intends to use the funds to finance the necessary clinical trials to achieve regulatory clearance and to start commercialization.
Founded by Dr. Andreas Schumacher, Dr. Benedict Doorschodt, Prof. Dr. René Tolba, PD. Dr. Christian Bleilevens, Prof. Dr. Malte Brettel and Marius Rosenberg, Vivalyx is a life science startup that has developed technology for revitalizing donor organs with the aim of increasing their vitality and thus increasing the number of organs available for life-saving transplants. Their novel liquid Vivalyx Omnisol is fully synthetic, works for perfusion at body-temperature, and is meant for cold and warm perfusion and static cold storage with expected beneficial clinical outcomes.
FinSMEs
01/05/2024